Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

15/08/2025 Eastern Time in USA The Dow Jones Industrial Average rose by 0.08%, closing at 44946.12 points; the Nasdaq Composite dropped by 0.4%, closing at 21622.98 points; the S&P 500 Index dropped by 0.29%, closing at 6449.8 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

IO Biotech, Inc.: Overnight gain 68.8%, Anticipation builds for key cancer vaccine trial results, boosting investor confidence despite analyst caution.

IO Biotech, Inc. (NASDAQ: IOBT) is a clinical-stage biopharmaceutical company at the forefront of developing novel cancer immunotherapies. The company's proprietary T-win technology platform underpins its innovative approach to oncology treatment, focusing on activating the immune system while simultaneously targeting and disrupting multiple tumor-induced immunosuppressive pathways. The company's pipeline of candidate products represents a potentially significant advancement in cancer management, with the potential to become cornerstone therapies for a wide range of solid tumors. IO Biotech's T-win platform employs a cutting-edge approach to cancer immunotherapy by leveraging the activation of endogenous T cells to target immunosuppressive mechanisms. This innovative strategy positions IO Biotech as a potential leader in the next generation of immuno-oncology treatments, addressing the growing need for more effective and targeted cancer therapies. As the company progresses through clinical trials, investors and industry observers are closely monitoring its developments, which could potentially reshape the landscape of cancer treatment.

IO Biotech, Inc. (IOBT) shares surged 68.8% on anticipation of pivotal Phase 3 trial results for its lead cancer vaccine candidate, Cylembio®, in combination with KEYTRUDA® for advanced melanoma treatment. Preliminary data suggests improved progression-free survival compared to monotherapy, with a favorable safety profile. The company plans to discuss regulatory pathways with the FDA to advance commercialization. Cylembio® has received FDA Breakthrough Therapy Designation, underscoring its potential value. Despite Morgan Stanley lowering its price target, it maintained an "Overweight" rating, reflecting market confidence in IOBT's prospects. These factors have contributed to the stock's impressive 134.8% year-to-date gain. The company's progress in cancer immunotherapy and potential market entry have sparked investor interest in this emerging biotech player.

PRECIGEN INC: Overnight gain 58.9%, FDA approves PAPZIMEOS for RRP treatment, boosting market confidence and analyst ratings

Precigen, Inc. (NASDAQ: PGEN) is a pioneering biopharmaceutical company at the forefront of the rapidly evolving field of synthetic biology. The firm specializes in developing next-generation gene and cell therapies, leveraging cutting-edge technologies to drive innovation in biological systems and deliver breakthrough advancements in healthcare. The company's roots trace back to 1998 when Dr. Thomas D. Reed founded Genomatix LLC in Ohio. In 2004, the entity underwent a strategic merger, reincorporating as a Virginia-based corporation. Subsequently, in 2005, the company rebranded as Intrexon, signaling its expanding focus and capabilities. Precigen's core mission revolves around harnessing the principles of synthetic biology to revolutionize medical treatments. By applying advanced genetic engineering techniques and proprietary platforms, the company aims to address unmet medical needs and transform patient outcomes across various therapeutic areas. As a leader in the biotechnology sector, Precigen continues to push the boundaries of scientific innovation, potentially unlocking new possibilities in personalized medicine and targeted therapies. The company's robust pipeline and commitment to research and development position it as a key player in the evolving landscape of gene and cell-based treatments.

PRECIGEN INC (PGEN) shares surged on multiple positive developments. The FDA granted full approval for PAPZIMEOS, the company's groundbreaking treatment for adult recurrent respiratory papillomatosis (RRP), marking the first FDA-approved therapy for this condition. Notably, the approval was granted without the need for additional confirmatory trials, expediting the product's market entry. Clinical trial results were highly encouraging, with 51% of patients achieving complete remission within 12 months of PAPZIMEOS treatment, and the majority maintaining remission at 24 months. Market sentiment improved as analysts revised their outlooks: HC Wainwright & Co. raised its price target from $6 to $8.50, while JP Morgan upgraded PRECIGEN INC (PGEN) from Underweight to Neutral, reflecting growing confidence in the company's prospects.

Sunrun Inc.: Overnight gain 32.8%, Clean energy trend, strong financials, and analyst upgrades boost investor confidence in solar provider.

Sunrun Inc., a pioneering force in the residential solar energy sector, was established in 2007 as a limited liability company in California. The company has positioned itself as a leader in providing innovative clean energy solutions, with a primary focus on helping homeowners significantly reduce their energy costs. Through its groundbreaking solar-as-a-service model, Sunrun Inc. enables customers to capitalize on the economic and environmental benefits of renewable energy while simultaneously decreasing their reliance on traditional utilities. This innovative approach not only promotes sustainability but also offers clients a more flexible and cost-effective energy alternative. The company's business model has been instrumental in democratizing access to solar power, allowing a broader range of consumers to adopt clean energy solutions without the need for substantial upfront investments. By leveraging its expertise in solar technology and financing, Sunrun Inc. has established itself as a key player in the ongoing transition towards a more sustainable energy landscape. As the renewable energy sector continues to evolve, Sunrun Inc.'s strategic positioning and commitment to innovation place it at the forefront of the residential solar market, poised for potential growth and expansion in the coming years.

Sunrun Inc. (RUN) has experienced a notable surge in stock price, driven by multiple factors. As a leading provider of residential solar systems in the United States, Sunrun has benefited from the overall growth trend in the clean energy sector, with solar energy stocks generally performing well. The company's robust financial performance, highlighted by an impressive net profit margin of 49.14%, significantly exceeding the industry average, demonstrates its strong profitability. Furthermore, several prominent institutional analysts have recently raised their target prices for Sunrun, bolstering investor confidence. The addition of Sunrun to the portfolio of Soros Fund Management in the first quarter has further strengthened market sentiment towards the company. These factors collectively contribute to the positive momentum observed in Sunrun's stock performance.

The Top 10 Daily Gainers in the USA market are listed as follows:

Editor's note: This content was generated by Sahm's in-house AI-enabled SaaS tool and was reviewed by our editing team.